ACIP Postponed Meningococcal Vaccine Schedule Review

The committee delayed updates to the immunization schedule following the recent introduction of pentavalent vaccines.

Updated on Sept. 30, 2026 in COVID-19

ACIP Postponed Meningococcal Vaccine Schedule Review

Live Poll

Should federal policy require universal vaccination rather than relying on shared clinical decision-making?

The Advisory Committee on Immunization Practices has postponed its planned review of the national meningococcal vaccine schedule. This delay follows the introduction of pentavalent vaccines and a need for further evaluation regarding clinical recommendations.

Why it matters

The committee aims to refine recommendations for MenACWY and MenB vaccines, especially as shared clinical decision-making protocols evolve. Health experts anticipate that shifts toward risk-based guidance could impact overall vaccination uptake.

Invasive meningococcal disease results in approximately 500 cases annually in the United States, with a 12% fatality rate. About 20% of survivors experience long-term sequelae following the infection.

The players

Advisory Committee on Immunization Practices

This federal advisory group provides guidance to the CDC on the most effective use of vaccines for the population.

The details

The committee currently recommends MenACWY vaccines for adolescents at ages 11-12 with a booster at age 16, while MenB vaccines are suggested for individuals aged 16-23. Pentavalent vaccines are now recommended when both MenACWY and MenB components are indicated at a single visit to simplify administration.

Adolescents receive their initial MenACWY vaccine at ages 11-12.
A MenACWY booster is administered at age 16.
The recommended age range for MenB vaccination is between 16 and 23.

Health Landscape

This decision marks a temporary pause in the Advisory Committee on Immunization Practices vaccine schedule as officials reconcile new pentavalent options with existing clinical guidelines. Such shifts highlight the complex integration of new vaccine technologies into established public health protocols.

Parents and patients should continue following existing age-based vaccination schedules while the committee reviews future guidelines. Physicians will continue to use shared clinical decision-making to determine if MenB vaccines are appropriate for individuals aged 16-23.

The takeaway

Patients should consult their primary care providers to discuss their specific risk factors and current vaccine eligibility requirements. Staying up to date on recommended booster shots remains the primary method for preventing invasive meningococcal disease.